Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry

PURPOSE: Immediate and proper implementation of a new and more potent therapy is important to ensure that the patient achieves the best possible outcome. This study aimed to examine whether the real-world overall survival (OS) has improved in patients with human epidermal growth factor receptor 2-po...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibragimova, Khava I. E., Geurts, Sandra M. E., Croes, Sander, Erdkamp, Frans, Heijns, Joan B., Tol, Jolien, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., Dercksen, Marcus W., Pepels, Manon J. A. E., Peters, Natascha A. J. B., van de Winkel, Linda, Tilli, Dominique J. P., Vriens, Ingeborg J. H., de Boer, Maaike, Tjan-Heijnen, Vivianne C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260428/
https://www.ncbi.nlm.nih.gov/pubmed/33743103
http://dx.doi.org/10.1007/s10549-021-06178-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260428/
https://www.ncbi.nlm.nih.gov/pubmed/33743103
http://dx.doi.org/10.1007/s10549-021-06178-8

Ejemplares similares